Amine Belhabri

10PUBLICATIONS
129CO-AUTHORS
Medical infection agents (incl. prions)Gene and molecular therapyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 17, 2026
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 13, 2026
Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

|Mar 19, 2026
Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.

Léa Barral, Nicolas Lespinasse, Camila Martin Cardozo

|Oct 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

Patrice Chevallier, Thibaut Leguay, Marc Delord

|Jun 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli

Pageof 2

Frequent Collaborators

4 joint publications

Emmanuelle Tavernier

3 joint publications

Christian Récher

3 joint publications

Nicolas Boissel

3 joint publications

Rathana Kim